A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

Inclusion Criteria:

• Eligible for continuing Roche IMP-based therapy at the time of roll-over from theparent study, as per the parent study protocol OR

• Eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsoredstudy as per the parent study protocol, with no access to commercially availablecomparator agent

• First dose of study treatment in this extension study will be received within 7 daysof the treatment interruption window allowed by the parent study

• Continue to benefit from the Roche IMP-based therapy or comparator at the time ofroll-over from the parent study as assessed by the investigator

• Ability to comply with the extension study protocol, per Investigator's judgement

Exclusion Criteria:

• Meet any of the study treatment discontinuation criteria specified in the parentstudy at the time of enrollment in this extension study

• Study treatment or comparator agent is commercially marketed in the participant'scountry for the participant-specific disease and is accessible to the participant

• Treatment with any anti-cancer treatment (other than treatment permitted in theparent study) during the time between last treatment in the parent study and thefirst dose of study treatment in this extension study

• Permanent discontinuation of all study treatment(s) or comparator agent(s) for anyreason during the parent study or during the time between last treatment in theparent study and the first dose of study treatment in this extension study (ifapplicable)

• Ongoing SAE(s) that has not resolved to baseline level or Grade ≤1 from the parentstudy or during the time between the last treatment in the parent study and thefirst dose of study treatment in this extension study

• Concurrent participation in any therapeutic clinical trial (other than the parentstudy)